Meta Platforms, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Meta Platforms, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $40.65B | Feb 1, 2018 |
| FY2017 | Dec 31, 2016 | $27.64B | Feb 1, 2018 |
| FY2017 | Dec 31, 2015 | $17.93B | Feb 1, 2018 |
| FY2016 | Dec 31, 2014 | $12.47B | Feb 3, 2017 |
| FY2015 | Dec 31, 2013 | $7.87B | Jan 28, 2016 |
| FY2014 | Dec 31, 2012 | $5.09B | Jan 29, 2015 |
| FY2013 | Dec 31, 2011 | $3.71B | Jan 31, 2014 |
| FY2012 | Dec 31, 2010 | $1.97B | Feb 1, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $200.97B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $164.50B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $134.90B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $116.61B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $117.93B | Feb 2, 2024 |
| FY2022 | Dec 31, 2020 | $85.97B | Feb 2, 2023 |
| FY2021 | Dec 31, 2019 | $70.70B | Feb 3, 2022 |
| FY2020 | Dec 31, 2018 | $55.84B | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $40.65B | Jan 30, 2020 |
| FY2018 | Dec 31, 2016 | $27.64B | Jan 31, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $60.46B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $62.36B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $39.10B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $23.20B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $39.37B | Feb 2, 2024 |
| FY2022 | Dec 31, 2020 | $29.15B | Feb 2, 2023 |
| FY2021 | Dec 31, 2019 | $18.49B | Feb 3, 2022 |
| FY2020 | Dec 31, 2018 | $22.11B | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $15.93B | Jan 30, 2020 |
| FY2018 | Dec 31, 2016 | $10.22B | Jan 31, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $83.28B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $69.38B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $46.75B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $28.94B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $46.75B | Feb 2, 2024 |
| FY2022 | Dec 31, 2020 | $32.67B | Feb 2, 2023 |
| FY2021 | Dec 31, 2019 | $23.99B | Feb 3, 2022 |
| FY2020 | Dec 31, 2018 | $24.91B | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $20.20B | Jan 30, 2020 |
| FY2018 | Dec 31, 2016 | $12.43B | Jan 31, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.37B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $43.87B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $38.48B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $35.34B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $24.66B | Feb 2, 2024 |
| FY2022 | Dec 31, 2020 | $18.45B | Feb 2, 2023 |
| FY2021 | Dec 31, 2019 | $13.60B | Feb 3, 2022 |
| FY2020 | Dec 31, 2018 | $10.27B | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $7.75B | Jan 30, 2020 |
| FY2018 | Dec 31, 2016 | $5.92B | Jan 31, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $115.80B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $91.33B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $71.11B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $50.48B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $57.68B | Feb 2, 2024 |
| FY2022 | Dec 31, 2020 | $38.75B | Feb 2, 2023 |
| FY2021 | Dec 31, 2019 | $36.31B | Feb 3, 2022 |
| FY2020 | Dec 31, 2018 | $29.27B | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $24.22B | Jan 30, 2020 |
| FY2018 | Dec 31, 2016 | $16.11B | Jan 31, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.69B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $37.26B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $27.05B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $31.19B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $18.69B | Feb 2, 2024 |
| FY2022 | Dec 31, 2020 | $15.16B | Feb 2, 2023 |
| FY2021 | Dec 31, 2019 | $15.10B | Feb 3, 2022 |
| FY2020 | Dec 31, 2018 | $13.92B | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $6.73B | Jan 30, 2020 |
| FY2018 | Dec 31, 2016 | $4.49B | Jan 31, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $366.02B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $276.05B | Jan 29, 2026 |
| FY2024 | Dec 31, 2023 | $229.62B | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | $185.73B | Feb 2, 2024 |
| FY2022 | Dec 31, 2021 | $165.99B | Feb 2, 2023 |
| FY2021 | Dec 31, 2020 | $159.32B | Feb 3, 2022 |
| FY2020 | Dec 31, 2019 | $133.38B | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | $97.33B | Jan 30, 2020 |
| FY2018 | Dec 31, 2017 | $84.52B | Jan 31, 2019 |
| FY2017 | Dec 31, 2016 | $64.96B | Feb 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $148.78B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $93.42B | Jan 29, 2026 |
| FY2024 | Dec 31, 2023 | $76.46B | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | $60.01B | Feb 2, 2024 |
| FY2022 | Dec 31, 2021 | $41.11B | Feb 2, 2023 |
| FY2021 | Dec 31, 2020 | $31.03B | Feb 3, 2022 |
| FY2020 | Dec 31, 2019 | $32.32B | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | $13.21B | Jan 30, 2020 |
| FY2018 | Dec 31, 2017 | $10.18B | Jan 31, 2019 |
| FY2017 | Dec 31, 2016 | $5.77B | Feb 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $217.24B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $182.64B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $153.17B | Jan 29, 2026 |
| FY2025 | Dec 31, 2022 | $125.71B | Jan 29, 2026 |
| FY2024 | Dec 31, 2021 | $124.88B | Jan 30, 2025 |
| FY2023 | Dec 31, 2020 | $128.29B | Feb 2, 2024 |
| FY2022 | Dec 31, 2019 | $101.05B | Feb 2, 2023 |
| FY2021 | Dec 31, 2018 | $84.13B | Feb 3, 2022 |
| FY2020 | Dec 31, 2017 | $74.35B | Jan 28, 2021 |
| FY2019 | Dec 31, 2016 | $59.19B | Jan 30, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.53B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $20.65B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $20.65B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $20.31B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $19.20B | Feb 2, 2024 |
| FY2022 | Dec 31, 2020 | $19.05B | Feb 2, 2023 |
| FY2021 | Dec 31, 2019 | $18.72B | Feb 3, 2022 |
| FY2020 | Dec 31, 2018 | $18.30B | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $18.22B | Jan 30, 2020 |
| FY2018 | Dec 31, 2016 | $18.12B | Jan 31, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $121.18B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $102.51B | Jan 29, 2026 |
| FY2024 | Dec 31, 2023 | $82.07B | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | $64.80B | Feb 2, 2024 |
| FY2022 | Dec 31, 2021 | $69.76B | Feb 2, 2023 |
| FY2021 | Dec 31, 2020 | $77.35B | Feb 3, 2022 |
| FY2020 | Dec 31, 2019 | $55.69B | Jan 28, 2021 |
| FY2019 | Dec 31, 2018 | $41.98B | Jan 30, 2020 |
| FY2018 | Dec 31, 2017 | $33.99B | Jan 31, 2019 |
| FY2017 | Dec 31, 2016 | $21.67B | Feb 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $35.87B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $43.89B | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | $41.86B | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | $14.68B | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | $16.60B | Feb 2, 2024 |
| FY2022 | Dec 31, 2020 | $17.58B | Feb 2, 2023 |
| FY2021 | Dec 31, 2019 | $19.08B | Feb 3, 2022 |
| FY2020 | Dec 31, 2018 | $10.02B | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | $8.08B | Jan 30, 2020 |
| FY2018 | Dec 31, 2016 | $8.90B | Jan 31, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.74B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $28.83B | Jan 29, 2026 |
| FY2024 | Dec 31, 2023 | $18.39B | Jan 30, 2025 |
| FY2023 | Dec 31, 2022 | $9.92B | Feb 2, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 23 | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | 24 | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | 15 | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | 8 | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | 13 | Feb 2, 2024 |
| FY2022 | Dec 31, 2020 | 10 | Feb 2, 2023 |
| FY2021 | Dec 31, 2019 | 6 | Feb 3, 2022 |
| FY2020 | Dec 31, 2018 | 7 | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | 5 | Jan 30, 2020 |
| FY2018 | Dec 31, 2016 | 3 | Jan 31, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 23 | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | 23 | Jan 29, 2026 |
| FY2025 | Dec 31, 2023 | 14 | Jan 29, 2026 |
| FY2024 | Dec 31, 2022 | 8 | Jan 30, 2025 |
| FY2023 | Dec 31, 2021 | 13 | Feb 2, 2024 |
| FY2022 | Dec 31, 2020 | 10 | Feb 2, 2023 |
| FY2021 | Dec 31, 2019 | 6 | Feb 3, 2022 |
| FY2020 | Dec 31, 2018 | 7 | Jan 28, 2021 |
| FY2019 | Dec 31, 2017 | 5 | Jan 30, 2020 |
| FY2018 | Dec 31, 2016 | 3 | Jan 31, 2019 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.33B | Jan 29, 2026 |
| FY2025 | Sep 30, 2025 | $1.32B | Jan 29, 2026 |
| FY2025 | Jun 30, 2025 | $1.32B | Jan 29, 2026 |
| FY2025 | Mar 31, 2025 | $1.33B | Jan 29, 2026 |
| FY2025 | Dec 31, 2024 | $1.27B | Jan 29, 2026 |
| FY2025 | Sep 30, 2024 | $1.26B | Jan 29, 2026 |
| FY2025 | Jun 30, 2024 | $1.27B | Jan 29, 2026 |
| FY2025 | Mar 31, 2024 | $1.27B | Jan 29, 2026 |